Edwards Lifesciences Wins $392 Million in Medtronic Case
This article is for subscribers only.
Edwards Lifesciences Corp., awarded more than $392 million in a patent-infringement lawsuit against Medtronic Inc., plans to ask a judge to prevent its rival from selling a new heart-valve device in the U.S.
Medtronic was set to begin selling its CoreValve by April pending Food and Drug Administration clearance, one of the biggest medical-device approvals anticipated by investors this year. Edwards has had the U.S. market to itself for the aortic valves inserted without cracking the chest since November 2011.